These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 7727433)
1. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Enjyoji K; Miyata T; Kamikubo Y; Kato H Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433 [TBL] [Abstract][Full Text] [Related]
2. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Wesselschmidt R; Likert K; Girard T; Wun TC; Broze GJ Blood; 1992 Apr; 79(8):2004-10. PubMed ID: 1562726 [TBL] [Abstract][Full Text] [Related]
3. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. Huang ZF; Wun TC; Broze GJ J Biol Chem; 1993 Dec; 268(36):26950-5. PubMed ID: 8262929 [TBL] [Abstract][Full Text] [Related]
4. Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Mine S; Yamazaki T; Miyata T; Hara S; Kato H Biochemistry; 2002 Jan; 41(1):78-85. PubMed ID: 11772005 [TBL] [Abstract][Full Text] [Related]
5. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347 [TBL] [Abstract][Full Text] [Related]
7. Tissue factor pathway inhibitor; its structure, function and clinical significance. Kato H Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630 [TBL] [Abstract][Full Text] [Related]
8. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Hamamoto T; Kisiel W Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000 [TBL] [Abstract][Full Text] [Related]
9. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. Kamikubo Y; Nakahara Y; Takemoto S; Hamuro T; Miyamoto S; Funatsu A FEBS Lett; 1997 Apr; 407(1):116-20. PubMed ID: 9141493 [TBL] [Abstract][Full Text] [Related]
10. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor. Lockett JM; Mast AE Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795 [TBL] [Abstract][Full Text] [Related]
11. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. Kamei S; Kamikubo Y; Hamuro T; Fujimoto H; Ishihara M; Yonemura H; Miyamoto S; Funatsu A; Enjyoji K; Abumiya T J Biochem; 1994 Apr; 115(4):708-14. PubMed ID: 8089087 [TBL] [Abstract][Full Text] [Related]
12. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. Abumiya T; Enjyoji K; Kokawa T; Kamikubo Y; Kato H J Biochem; 1995 Jul; 118(1):178-82. PubMed ID: 8537308 [TBL] [Abstract][Full Text] [Related]
13. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa. Peraramelli S; Suylen DP; Rosing J; Hackeng TM Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666 [TBL] [Abstract][Full Text] [Related]
14. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Jesty J; Wun TC; Lorenz A Biochemistry; 1994 Oct; 33(42):12686-94. PubMed ID: 7918495 [TBL] [Abstract][Full Text] [Related]
15. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain. Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595 [TBL] [Abstract][Full Text] [Related]
16. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Piro O; Broze GJ Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366 [TBL] [Abstract][Full Text] [Related]
17. A kinetic analysis of the interaction of human recombinant tissue factor pathway inhibitor with factor Xa utilizing and immunoassay and the effect of antithrombin III/heparin on the complex formation. Kamikubo Y; Hamuro T; Takemoto S; Nakahara Y; Kamei S; Nakagaki T; Miyamoto S; Funatsu A; Kato H Thromb Res; 1998 Feb; 89(4):179-86. PubMed ID: 9651145 [TBL] [Abstract][Full Text] [Related]
18. Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa. Day KC; Welsch DJ Thromb Res; 1992 Dec; 68(4-5):369-81. PubMed ID: 1290165 [TBL] [Abstract][Full Text] [Related]
20. Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Hamamoto T; Kisiel W Thromb Res; 1995 Nov; 80(4):291-7. PubMed ID: 8585041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]